Dihydrofolate Reductase Inhibitor Antibacterial Drug Class List

Drugs in Drug Class: Dihydrofolate Reductase Inhibitor Antibacterial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE	polymyxin b sulfate; trimethoprim sulfate	SOLUTION/DROPS;OPHTHALMIC	064211-001	Apr 13, 1998	AT	RX	No	Yes
Epic Pharma Llc	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE	polymyxin b sulfate; trimethoprim sulfate	SOLUTION/DROPS;OPHTHALMIC	065006-001	Dec 17, 1998	AT	RX	No	No
Bausch And Lomb	TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE	polymyxin b sulfate; trimethoprim sulfate	SOLUTION/DROPS;OPHTHALMIC	064120-001	Feb 14, 1997	AT	RX	No	No

Market dynamics and patent landscape for Dihydrofolate reductase (DHFR) inhibitor antibacterials

Last updated: April 24, 2026

What is the DHFR inhibitor antibacterial market and where does demand concentrate?

DHFR inhibitor antibacterials are dominated by a small set of systemic agents: trimethoprim (TMP) and pyrimethamine (PMP, primarily antiprotozoal), with most antibacterial use occurring through trimethoprim-containing fixed combinations, most notably trimethoprim/sulfamethoxazole (TMP-SMX). Patent activity for DHFR antibacterials is limited by (i) early first approvals for TMP and TMP-SMX, (ii) broad generic penetration globally, and (iii) reformulation and combination strategies that tend to fall outside long-term exclusivity unless anchored to new chemical entities, new formulations with meaningful clinical differentiation, or new dosing/regimen IP that withstands regulatory and obviousness scrutiny.

Demand concentration by use pattern

• Community and outpatient infections: TMP-SMX has durable use in uncomplicated urinary tract infections and skin/soft tissue indications in many markets, plus broader off-label use in respiratory and other bacterial indications depending on local stewardship guidance.
• Resistance and susceptibility constraints: market utilization tracks local resistance to TMP and TMP-SMX, with formulary access often tightening where resistance rises.
• Competition from other oral agents: in many geographies, fluoroquinolones, beta-lactams, doxycycline, and newer oral agents pressure TMP-SMX share in acute care pathways.
• Hospital stewardship: use is shaped by guideline positioning and antimicrobial stewardship controls rather than “new class” adoption.

Commercial structure

• Core revenue is generic in most major markets because the pivotal actives (TMP, TMP-SMX) have long since cleared primary patent barriers.
• Value-add differentiation tends to shift to:
  • brand/packaging strategies where allowed,
  • dosage forms tied to patient adherence,
  • and combination/regimen IP rather than DHFR enzyme-binding novelty.

Which DHFR inhibitors define the antibacterial patent and commercial landscape?

Within the DHFR inhibitor antibacterial class, the practical antibacterial “anchor” is trimethoprim (alone or with sulfonamides). Pyrimethamine is a DHFR inhibitor but is principally used as an antiprotozoal drug; its patent and market story therefore sits closer to antimalarial and toxoplasmosis use than to “antibacterial” utilization.

Key actives and their relationship to antibacterial use

• Trimethoprim (TMP): antibacterial use is typically through systemic therapy, frequently in fixed combinations.
• Trimethoprim/sulfamethoxazole (TMP-SMX): the dominant DHFR inhibitor antibacterial commercial format in many markets.
• Pyrimethamine (PMP): DHFR inhibitor, but antibacterial labeling is not the primary market driver.

How do patent protections typically appear for DHFR antibacterials after generics enter?

Patent landscape dynamics for DHFR inhibitors in antibacterials follow a recurring pattern:

1) Primary patents for early actives age out

• TMP and the canonical TMP-SMX combination entered the market decades ago.
• As a result, primary chemical composition and key process patents have expired in most jurisdictions for current commercialization.

2) Secondary IP clusters around life-cycle management

When exclusivity exists, it usually reflects one of these:

• New salts/solvates or polymorphs for existing actives
• Novel fixed-dose combinations with specific ratios, additional components, or new clinical use claims
• Reformulations (extended release, pediatric-friendly dosing forms, improved bioavailability)
• Manufacturing process improvements that may be patentable but often do not block generics unless claim scope is enforceable and not obvious
• Use patents (new indications, new patient subsets, or new dosing regimens)

In practice, for widely generic classes like DHFR antibacterials, enforceable secondary IP is often fragmented across jurisdictions and claim sets, limiting the ability to sustain premium pricing.

What does the competitive and pricing environment look like?

Generic-led pricing pressure

• TMP and TMP-SMX are widely available as generics, driving low price points.
• Brand positioning, where present, depends on:
  • contract formularies,
  • supply reliability,
  • and patient adherence advantages tied to dosage form rather than to differentiated pharmacology.

Resistance-driven formulary volatility

• TMP resistance in key pathogens can reduce guideline support.
• This volatility affects volume, not just pricing, and can reshape which combinations and dosage strengths remain stocked.

Substitution among oral anti-infectives

• TMP-SMX faces ongoing substitution from:
  • beta-lactams (penicillins/cephalosporins),
  • doxycycline and other tetracyclines,
  • macrolides in select indications,
  • and more recent agents where local guidelines favor them.

Where are the near-term patent cliffs and exclusivity opportunities likely to be?

Because the canonical actives have long ago cleared initial patent terms, the realistic “opportunity set” for new entrants is limited to:

• New chemical entities that inhibit DHFR with improved potency, resistance circumvention, or safety profile
• New combination regimens that are novel enough for enforceable secondary patents and that support differentiated regulatory labeling
• Next-generation formulations that meet regulatory thresholds and can be protected without being trivially obvious

For DHFR antibacterials specifically, the overall landscape tends to favor incremental improvements rather than broad, class-defining new patent estates.

How do regulatory exclusivity mechanics influence the patent landscape?

Regulatory exclusivity interacts with patent value in a class where chemical novelty is rare:

• Where new formulations or new fixed-dose combinations gain approval with meaningful clinical data, they can anchor additional IP layers.
• Where the science is incremental and claims are easy to design around, generic entry accelerates and patent enforcement risk rises.

The resulting market dynamic is that exclusivity, when it exists, is often shorter and more jurisdiction-specific than investors expect from a “new class” narrative.

What are the practical takeaways for R&D portfolios targeting DHFR antibacterials?

1) Compete on differentiation, not on DHFR inhibition alone

DHFR inhibition is a known mechanism. Patent defensibility depends on:

• molecular novelty (new DHFR-binding chemistry),
• combination rationales supported by data that map to non-obvious claim scope,
• and label-linked exclusivity that creates enforceable “hooks” against designed-around generics.

2) Expect dense generic competition around the core actives

For TMP/TMP-SMX, the commercial base is generic. Any new program must clear a high bar:

• regulatory differentiation,
• patent enforceability,
• and payer/formulary acceptance under stewardship frameworks.

3) Plan around claim design-around risk

Secondary IP (formulations, polymorphs, ratios, regimens) is frequently vulnerable to:

• obviousness challenges,
• alternative design around,
• and enforcement limitations.

Key Takeaways

• DHFR inhibitor antibacterials are commercially dominated by trimethoprim and TMP-SMX, which sit in a generic-led market structure.
• The patent landscape is characterized by aged primary IP and limited secondary exclusivity, typically from formulation, combination, or use-regimen claims.
• Near-term investable opportunities generally require true differentiation (new chemistry or defensible combination/regimen + label linkage), not merely reiteration of established DHFR inhibition.
• Resistance patterns and stewardship guidance shape demand more than patent events in mature markets.

FAQs

1. Is trimethoprim/sulfamethoxazole the main DHFR inhibitor antibacterial with ongoing market volume?
   Yes. TMP-SMX is the central DHFR inhibitor format for antibacterial use in most markets due to long-established clinical adoption and generic availability.

2. Do DHFR inhibitor antibacterials have large ongoing primary patent estates?
   Typically no. The key antibacterial actives have long passed the era of primary patent-driven market exclusivity.

3. What secondary patent types most often appear for DHFR antibacterials?
   Reformulations, fixed-dose combinations with specific ratios or additional components, polymorph/salt strategies, and use or regimen claims.

4. How does antimicrobial resistance affect the market more than patent protection?
   Resistance changes susceptibility and guideline support, which impacts formularies and utilization even if patent status is unchanged.

5. What must a new DHFR inhibitor antibacterial program show to be patent-relevant?
   It needs molecular or regimen differentiation that supports enforceable, non-obvious claims and, ideally, label-linked regulatory exclusivity.

References

[1] U.S. Food and Drug Administration (FDA). Drug Approval Reports and related drug labeling for trimethoprim, sulfamethoxazole, and trimethoprim-sulfamethoxazole. FDA Drug Approval package pages and label archives.